A patient who is at risk for osteoporosis will begin taking the selective estrogen receptor modulator raloxifene [Evista]. Which statement will the nurse include when teaching this patient about the medication?
A) Raloxifene reduces the risk of thromboembolism.
B) The drug is associated with an increased risk of breast cancer.
C) Use of this drug increases the risk of endometrial carcinoma.
D) Vasomotor symptoms are a common side effect of this drug.

Question

Quizplus · Accepted Answer

Raloxifene can induce hot flashes in patients taking the drug. It increases the risk for thromboembolism. It protects against breast cancer and does not pose a risk of uterine cancer.

A Patient Who Is at Risk for Osteoporosis Will Begin